Acute myeloid leukemia treatment drug Mylotarg decided to re-discuss setting reimbursement standards. This drug received attention as the first Antibody-Drug Conjugate (ADC) treatment, but in May of last year, the Cancer Disease Review Committee failed to establish reimbursement standards. The HIRA (Chief Director Kang Jung-gu) announced that it decided to re-discuss Mylotarg as a result of the review of the reimbursement standards for drugs used in cancer patients, which were reviewed at the 5th Cancer Disease Review Committee in 2023 held on the 26th. This drug, licensed in Korea in December 2021, is an ADC consisting of a CD33-targeting monoclonal antibody and calicheamicin, a cytotoxic drug, and blocks cancer cell gr